José Valentín
García Gutiérrez
Profesor/a Asociado/a en CC. de la Salud
Hospital Universitario de la Princesa
Madrid, EspañaHospital Universitario de la Princesa -ko ikertzaileekin lankidetzan egindako argitalpenak (30)
2024
-
Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)
Scientific Reports
-
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
Annals of Hematology
2023
-
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25
-
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors
Cancers, Vol. 15, Núm. 4
2022
-
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Scientific Reports, Vol. 12, Núm. 1
-
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
2021
-
Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission
Journal of Clinical Medicine, Vol. 10, Núm. 1, pp. 1-21
-
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Blood Cancer Journal
2020
-
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
Leukemia, Vol. 34, Núm. 8, pp. 2125-2137
-
Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection
Biochemical Pharmacology, Vol. 182
-
Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes
Journal of Molecular Diagnostics, Vol. 22, Núm. 10, pp. 1217-1224
-
Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
Bone Marrow Transplantation, Vol. 55, Núm. 3, pp. 641-648
2019
-
Immediate effects of dasatinib on the migration and redistribution of naïve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients
Frontiers in Pharmacology, Vol. 10
-
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients
Annals of Hematology, Vol. 98, Núm. 2, pp. 321-330
2018
-
Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase (Journal of Cancer Research and Clinical Oncology, (2017), 143, 10, (2059-2066), 10.1007/s00432-017-2445-z)
Journal of Cancer Research and Clinical Oncology
-
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098
-
Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors
Biochemical Pharmacology, Vol. 156, pp. 248-264
-
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
Blood Cancer Journal, Vol. 8, Núm. 10